Features ranked in the top five from each omic dataset also validated the capacity of our approach to recover well-established molecular processes associated with cancer (Fig. 4a), for example, CDKN2A copy number alterations, as well as sensitivity to the SRC family inhibitor, dasatinib. Here, CDKN2A is linked to cancer.